Monte Rosa Therapeutics, Inc.GLUEEarnings & Financial Report
Nasdaq · Health Care · Biological Products, (No Diagnostic Substances)
Monte Rosa Therapeutics is a clinical-stage biotechnology company specializing in the discovery and development of targeted molecular glue degrader therapies. Its pipeline addresses unmet medical needs across oncology, rare genetic disorders and immunological diseases, with operations focused on advancing novel treatments for global patient populations.
Top Holders
| Holder | % Owned | Shares | Change | As of |
|---|---|---|---|---|
| New Enterprise Associates 17, L.P. | 12.50% | 7.7M | ▼ -2.70pp | 2024-08-12 |
| T. ROWE PRICE ASSOCIATES, INC. | 10.80% | 6.6M | ▲ +0.60pp | 2024-11-14 |
| Baker Bros. Advisors LP | 9.80% | 4.9M | — | 2024-02-14 |
| Avoro Capital Advisors LLC | 9.10% | 4.5M | — | 2024-02-14 |
| FMR LLC | 8.31% | 5.1M | ▼ -2.74pp | 2024-11-12 |
| Versant Venture Capital VI, L.P. | 6.60% | 4.1M | ▼ -1.70pp | 2024-10-30 |
| BlackRock, Inc. | 4.70% | 2.4M | — | 2024-02-14 |
| Nos. of above persons | 0.00% | 61.2K | — | 2024-02-14 |
Insider Transactions
Net 90d: −$989.1K · buys $0 / sells $989.1KRange:
Action:
Role:
| Insider | Role | Action | ||||
|---|---|---|---|---|---|---|
| 2026-04-14 | Markus Warmuth | President & CEO | Sell (open market) | 8.0K | $17.64 | $141.1K |
| 2026-04-09 | Philip Nickson | Chief Business & Legal Officer | Sell (open market) | 5.8K | $17.69 | $103.4K |
| 2026-04-06 | Matthew Bowen | Principal Accounting Officer | Grant | 4.3K | — | — |
| 2026-03-04 | Edmund Dunn | Principal Accounting Officer | Sell (open market) | 139 | $17.96 | $2.5K |
| 2026-03-02 | Markus Warmuth | President & CEO | Sell (open market) | 5.5K | $17.92 | $98.0K |
| 2026-03-02 | Edmund Dunn | Principal Accounting Officer | Option exercise | 536 | $13.41 | $7.2K |
| 2026-03-02 | Edmund Dunn | Principal Accounting Officer | Sell (open market) | 536 | $17.50 | $9.4K |
| 2026-02-27 | Edmund Dunn | Principal Accounting Officer | Option exercise | 25.2K | $13.41 | $337.4K |
| 2026-02-27 | Edmund Dunn | Principal Accounting Officer | Sell (open market) | 25.2K | $18.10 | $455.5K |
| 2026-02-23 | Filip Janku | Chief Medical Officer | Sell (open market) | 9.2K | $19.50 | $179.2K |
1–10 of 10